5 trends tracked about this subject — the full history, oldest to newest below.
New research published in Nature demonstrates highly efficient base editing at the PCSK9 gene during normal human embryo development.
The FDA approves the first oral PCSK9 pill, Lipfendra, as Merck charts a long-term path.
Recent coverage examines how Lipfendra compares to traditional statins for lowering cholesterol.
Merck has achieved a regulatory milestone with the FDA approval of Lipfendra, the first-of-its-kind oral treatment for reducing cholesterol.
The FDA has approved Merck's Lipfendra, the first oral PCSK9 drug capable of lowering LDL cholesterol by nearly 60%.